SLC25A40促进人类白血病K562细胞的抗癌药物耐药性
Nodoka Kudo1, Rikuma Kouno1, Yoshihiko Shibayama1
1Department of Drug Formulation, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido.
Biological & pharmaceutical bulletin
|July 5, 2023
概括
溶解物载体家族25成员40 (SLC25A40) 基因在抗多克索鲁比的K562/ADM细胞中被上调,增强细胞增殖并影响耐药性. 降低SLC25A40的调节会降低谷氨水平和细胞生长.
科学领域:
- * 分子生物学 * 分子生物学
- * 癌症研究研究
- * 药物耐药机制 药物耐药机制
背景情况:
- *来自K562的K562/ADM细胞对多克索鲁比 (ADM) 呈现耐药性.
- * 过度表达P-糖蛋白是众所周知的多药性耐药性的原因.
- * 这项研究探讨了K562/ADM细胞中药物耐药性的新机制.
研究的目的:
- * 为了研究K562/ADM细胞中多克索鲁比抗性的新机制.
- * 分析溶解物载体 (SLC) 介导的跨膜运输基因的作用.
- * 确定SLC25A40在药物耐药性和细胞增殖中的特定功能.
主要方法:
- *基因本体学分析以确定差异表达的基因.
- *实时PCR测量基因表达水平 (SLC25A40,ABCB4,ADAM22) 进行测量.
- *研究SLC25A40对线粒体谷氨和细胞增殖的影响.
主要成果:
- *K562/ADM细胞中SLC介导的跨膜运输基因的显著更高的表达.
- * 在K562/ADM细胞中SLC25A40,ABCB4和ADAM22的升调.
- *下调SLC25A40降低了线粒体谷和细胞增殖.
结论:
- *SLC25A40在K562/ADM细胞中被上调,有助于增强细胞增殖.
- * SLC25A40表达影响多克索鲁比 (ADM) 耐药性.
- * SLC25A40代表了克服白血病药物耐药性的潜在目标.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K


